Aura Biosciences (AURA) Operating Leases (2021 - 2026)
Aura Biosciences' (AURA) quarterly Operating Leases came in at $13.7 million in Q1 2026, down 10.14% YoY from $15.3 million in Q1 2025, and down 2.9% on a QoQ basis from $14.1 million in Q4 2025.
Aura Biosciences (AURA) Operating Leases (2021 - 2026) Analysis & Trends
Aura Biosciences (AURA) has 6 years of Operating Leases data on file, last reported at $13.7 million in Q1 2026.
- Quarterly Operating Leases fell 10.14% year-over-year to $13.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.7 million (down 10.14% YoY) and the FY2025 annual result came in at $14.1 million, down 9.51% from the prior year.
- Operating Leases eased to $13.7 million in Q1 2026, from $14.1 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $18.1 million in Q3 2022 to a low of $51000.0 in Q2 2022.
- A 5-year average of $14.3 million and a median of $16.0 million in 2024 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2023 — Operating Leases soared 34031.37% — and 2026, when it retreated 10.14%.
- Tracing AURA's Operating Leases over 5 years: stood at $17.9 million in 2022, then retreated by 5.73% to $16.9 million in 2023, then dropped by 7.41% to $15.6 million in 2024, then slipped by 9.51% to $14.1 million in 2025, then slipped by 2.9% to $13.7 million in 2026.
- The last three Operating Leases figures came in at $13.7 million (Q1 2026), $14.1 million (Q4 2025), and $14.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Aura Biosciences | 797.49 Mn | 729.65 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.30 Mn |
| Mar 31, 2026 | 13.72 Mn |
| Dec 31, 2025 | 14.13 Mn |
| Sep 30, 2025 | 14.53 Mn |
| Jun 30, 2025 | 14.92 Mn |
| Mar 31, 2025 | 15.27 Mn |
| Dec 31, 2024 | 15.62 Mn |
| Sep 30, 2024 | 15.96 Mn |
| Jun 30, 2024 | 16.28 Mn |
| Mar 31, 2024 | 16.58 Mn |
| Dec 31, 2023 | 16.87 Mn |
| Sep 30, 2023 | 17.15 Mn |
| Jun 30, 2023 | 17.41 Mn |
| Mar 31, 2023 | 17.65 Mn |
| Dec 31, 2022 | 17.90 Mn |
| Sep 30, 2022 | 18.13 Mn |
| Jun 30, 2022 | 51,000.00 |
| Mar 31, 2022 | 206,000.00 |
| Dec 31, 2021 | 360,000.00 |
| Sep 30, 2021 | 513,000.00 |